Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics

Pharmaceutical Research

Volumn 30, Issue 9, 2013, Pages 2355-2367

  Combes, François Pierre ^a,b,c   Retout, Sylvie ^b,c   Frey, Nicolas ^c   Mentré, France ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Institut Roche de Recherche et Médecine Translationnelle   (France)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

bayesian fisher information matrix; non linear mixed effects model; optimal design; pharmacokinetics

Indexed keywords

ACCURACY; ARTICLE; BAYESIAN FISHER INFORMATION MATRIX; CONTROLLED STUDY; FIRST ORDER LINEARIZATION; INDIVIDUAL PARAMETER SHRINKAGE; INTERMETHOD COMPARISON; LINEAR SYSTEM; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MATHEMATICAL PARAMETERS; MONTE CARLO METHOD; NON LINEAR MIXED EFFECT MODEL; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; UNCERTAINTY;

BAYES THEOREM; MODELS, STATISTICAL; MONTE CARLO METHOD; NONLINEAR DYNAMICS; PHARMACOKINETICS;

EID: 84883262361     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1079-3     Document Type: Article

References (29)

1. Pillai GC, Mentré F, Steimer J-L. Non-linear mixed effects modeling - from methodology and software development to driving implementation in drug development science. J Pharmacokinet Pharmacodyn. 2005;32(2):161-83.
2. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. NONMEM User's guides. (1989-2009), Icon development Solutions, Ellicott City, USA 2009.
3. www.lixoft.com.
4. Al-Banna MK, Kelman AW. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm. 1990;18(4):347-60.
5. Holford NH, Kimko HC, Monteleone JP, Peck CC. Simulation of clinical trials. Annu Rev Pharmacol Toxicol. 2000;40:209-34.
6. Atkinson AC, Donev AN. Optimum experimental designs. Oxford: Oxford University Press; 1992.
7. Fisher RA. The logic of inductive inference. J R Stat Soc. 1935;98(1):39-54.
8. Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika. 1997;84(2):429-42.
9. Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat Med. 2002;21(18):2623-39.
10. Bazzoli C, Retout S, Mentré F. Design evaluation and optimisation in multiple response non-linear mixed effect models: PFIM 3.0. Comput Methods Prog Biomed. 2010;98(1):55-65.
11. Nyberg J, Ueckert S, Strömberg EA, Hennig S, Karlsson MO, Hooker AC. PopED: an extended, parallelized, nonlinear mixed effects models optimal design tool. Comput Methods Prog Biomed. 2012;108(2):789-805.
12. Gueorguieva I, Ogungbenro K, Graham G, Glatt S, Aarons L. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Comput Methods Prog Biomed. 2007;86(1):51-61.
13. http://www.winpopt.com/
14. Foo LK, Duffull S. Adaptive optimal design for bridging studies with an application to population pharmacokinetic studies. Pharm Res. 2012;29(6):1530-43.
15. Foo LK, Duffull S. Methods of robust design of non-linear models with an application to pharmacokinetics. J Biopharm Stat. 2010;20(4):886-902.
16. Retout S, Mentré F. Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn. 2003;30(6):417-43.
17. Merlé Y, Mentré F. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. J Pharmacokinet Biopharm. 1995;23(1):101-25.
18. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26(3):294-305.
19. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982;71(12):1344-8.
20. Fedorov F. Mixed models: design of experiments. Presented at Design and analysis of experiments, Cambridge, UK. 11th August 2011 (http://www.newton.ac. uk/programmes/DAE/seminars/081109301.html).
21. Savic RM, Karlsson MO. Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558-69.
22. Mentré F, Burtin P, Merlé Y, Van Bree J, Mallet A, Steimer J-L. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Inf J. 1995;29(3):997-1019.
23. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in subjects with rheumatoid arthritis. J Clin Pharmacol. 2010;50(7):754-66.
24. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
25. Pilz J. Bayesian estimation and experimental design in linear regression models. Leipzig: Teubner-Texte; 1983.
26. Boeckmann AJ, Sheiner LB, Beal SL. NONMEM users guide - Part V introductory guide. Ellicott City: Icon development Solutions; 2011.
27. McGree JM, Eccleston JA, Duffull SB. Compound optimal design criteria for nonlinear models. J Biopharm Stat. 2008;18(4):646-61.
28. Jones B, Wang J. Constructing optimal designs for fitting pharmacokinetic models. Stat Comput. 1999;9(3):209-18.
29. Jones B, Wang J, Jarvis P, Byrom W. Design of cross-over trials for pharmacokinetic studies. J Stat Plan Infer. 1999;78(1-2):307-16.